Stroke caused by small vessel occlusion in a patient taking etoricoxib and thalidomide

Journal of Neuroimaging

Volumn 17, Issue 1, 2007, Pages 87-88

  Wong, Edward H C ^a   Leung, Thomas W H ^a   Wong, K S Lawrence ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cox 2; Etoricoxib; Stroke; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ETORICOXIB; HYDROXYCHLOROQUINE; METHOTREXATE; PHOSPHOLIPID ANTIBODY; SALAZOSULFAPYRIDINE; STATIN; THALIDOMIDE;

ADULT; AORTA ATHEROSCLEROSIS; ARTHRITIS; ARTICLE; ARTIFICIAL EMBOLISM; BLOOD VESSEL OCCLUSION; CASE REPORT; CELL NUCLEUS INCLUSION BODY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HYPERLIPIDEMIA; INFARCTION; MALE; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; SMOKING; STROKE; THROMBOSIS; VASCULITIS;

ADULT; ARTHRITIS, RHEUMATOID; CEREBRAL INFARCTION; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACRANIAL THROMBOSIS; MALE; PYRIDINES; SULFONES; THALIDOMIDE;

EID: 33846085543     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2006.00071.x     Document Type: Article

References (7)

1. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-1711.
2. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lasas A, Konstam MA, Saron JA. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
3. Solomon SD, McMurry JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080.
4. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-2029.
5. Clark TE, Edom N, Larson J, Lindsay LJ. Thalomid (thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Safety 2001;24:87-117.
6. Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs 2002;62:2637-2651.
7. Cush JJ, Kavanaugh A, Matteson EL. The Safety of COX-2 Inhibitors, Deliberations from the February 16-18, 2005, FDA Meeting, American College of Rheumatology Hotline (05/03). Available at https://www.rheumatology.org/ publications/hotline/0305NSAIDs.asp